Corrigendum to DESTINY-Lung02 Trial Data in HER2-Mutant Metastatic NSCLC

Journal of Thoracic Oncology (JTO) published a clinical update in Oncology on 23 Feb 2026. The item focuses on Corrigendum to ‘Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02—A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC’ [Journal of Thoracic Oncology Volume 20 Issue 12 (2025) 1814-1828]. Review the original article for the full source wording and details.

Corrigendum to DESTINY-Lung02 Trial Data in HER2-Mutant Metastatic NSCLC

Clinical Briefing

Clinical Editorial

Source Reference

Related by Condition/Drug

Antibody-Drug Conjugates In Gynaecological Cancers: Current Landscape

Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trial

B7-H3 Antibody–Drug Conjugate Turning Immune Evasion Into Vulnerability

Trastuzumab Rezetecan in HER2-Expressing Advanced Gastric Cancer and Related Cancers: A Multicen

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in HER2-Mutant NSCLC Acr

Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in HER2-Positive